Lupin Limited has informed the Exchange that U.S. FDA has determined the inspection of Company's Pithampur Unit-2 manufacturing facility as Official Action Indicated.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has informed the stock exchanges that the U.S. FDA has classified its recent inspection of the Pithampur Unit-2 manufacturing facility as 'Official Action Indicated.' This is the most serious of the FDA's three inspection classifications, meaning the regulator found significant objectionable conditions during the inspection. An OAI typically precedes enforcement steps such as a warning letter, import alert, or restrictions on product approvals from that facility. Pithampur Unit-2 is a key plant in Lupin's U.S. generics supply chain, so any disruption could affect product approvals and supplies to the U.S. market.
Negative for shareholders — an OAI classification raises the risk of regulatory action that could delay or block new product approvals and disrupt U.S. supplies, putting pressure on revenue and the stock price in the near term.